View the slides for the "Living Well with Myeloma" Teleconference on CAR T-Cell Therapy
The next “Living Well with Myeloma” teleconference will focus on CAR T-Cell Therapy: What Myeloma Patients&Caregivers Need to Know. It takes place on Thursday, September 22, 2016 at 7 PM ET / 4 PM PT. Speakers are Dr. Rafat Abonour (Indiana Universityá Simon Cancer Center) and Dr. Edward Stadtmauer (University of Pennsylvania). CAR T cells, or chimeric antigen receptor T cells, are part of a class of cancer therapies known as immunotherapies. With CAR T-cell therapy, a patient's T cells are harvested and genetically reengineered to become better able to recognize and attack myeloma. The altered T cells are then reinfused into the body with the hope of fighting the disease. To learn about this exciting new therapy, register for free HERE. Pre-registration is highly recommended.
Contributors : Guy Ledergor ; Assaf Weiner ; Elli Papaemmanuil ; Ido AmitSeries Type : Expression profiling by high throughput sequencingOrganism : Homo sapiensMultiple myeloma (MM), a plasma cell (PC) malignancy, is the second most common blood cancer. Despite extensive research, disease heterogeneity within and between patients is poorly characterized, hampering efforts for early diagnosis and improved treatments. Here, we apply single cell RNA-seq to study the heterogeneity of 40 individuals along the MM progression spectrum. We define malignant PC at single cell resolution, demonstrating high inter-patient variability ...
(Weizmann Institute of Science) Israeli scientists and physicians develop a new technology for profiling the unique genetic makeup of myeloma tumor cells that will allow better diagnosis and treatment.
Multiple myeloma (MM) is a genetically heterogeneous cancer of bone marrow plasma cells with variable outcome. To assess the prognostic relevance of clonal heterogeneity of TP53 copy number, we profiled tumors from 1777 newly diagnosed Myeloma XI trial patients with multiplex ligation-dependent probe amplification (MLPA). Subclonal TP53 deletions were independently associated with shorter overall survival, with a hazard ratio of 1.8 (95% confidence interval, 1.2-2.8; P = .01). Clonal, but not subclonal, TP53 deletions were associated with clinical markers of advanced disease, specifically lower platelet counts (P
Cell-based immunotherapy approaches for multiple myeloma, Published online: 06 December 2018; doi:10.1038/s41416-018-0346-9Cell-based immunotherapy approaches for multiple myeloma
AbstractBased on ELOQUENT-2, combination therapy with the monoclonal antibody elotuzumab was approved for relapsed/refractory multiple myeloma in the US and Europe. However, outside clinical trials, the optimal integration of elotuzumab into the sequence of treatment lines remains to be determined. Therefore, we analyzed safety and efficacy of elotuzumab/immunomodulatory drug combinations in a real-life cohort of 33 patients from our institution. The most frequent grade 3/4 adverse event was lymphopenia which did not increase the incidence of viral reactivations. After a median of four prior treatment lines, an overall res...
Johnson&Johnson's blockbuster blood cancer drug Darzalex significantly reduced the risk of disease progression or death in patients who have not been previously treated for multiple myeloma, late-stage study data showed on Tuesday.
Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, said on Monday seven out of 10 patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.
Amgen Inc, updating the first trial of its bispecific antibody for multiple myeloma, on Monday said seven out of ten patients given the second-highest dose of AMG420 responded to the drug, including four with no detectable cancer.
(Dana-Farber Cancer Institute) Dana-Farber Cancer Institute scientists will present research marking significant advances against the hematologic cancer multiple myeloma at the ASH Annual Meeting.
AbstractThe commercial production of monoclonal antibodies (mAbs) has revolutionized the treatment of many diseases, including cancer, multiple sclerosis, and rheumatoid arthritis. These biotherapeutics have the potential to generate a global annual revenue of more than US$150 billion. Two cell hosts are predominantly utilized to produce these mAbs: Chinese hamster ovary (CHO) cells and murine myeloma cells (NS0). By 2017, nearly one-quarter of all approved mAbs in the market were produced using the NS0 host cell line, and around two-thirds were produced in CHO cells. Several different expression platforms are available: C...